# OH2 Oncolytic Viral Therapy in Solid Tumors

Source: https://onco.cc/trials/nct03866525/  
OnCo record `nct03866525` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of OH2 injection, with or without irinotecan or HX008 in advanced solid tumours, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.

## Summary

OH2 Oncolytic Viral Therapy in Solid Tumors is a phase 1/2 interventional study registered as NCT03866525 by Binhui Biopharmaceutical Co., Ltd., with 300 participants planned, started 2019-04-02 and due to reach its primary completion in 2025-08-30. Interventions recorded: OH2 injection, with or without irinotecan or HX008.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03866525
- Phase: 1/2
- Setting: Phase I/II Study of OH2 Injection, an Oncolytic Type 2 Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor, in Malignant Solid Tumors
- Sponsor: Binhui Biopharmaceutical Co., Ltd.
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT03866525: https://clinicaltrials.gov/study/NCT03866525

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Binhui Biopharmaceutical](https://onco.cc/companies/binhui-biopharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct03866525.json